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Metabolic bone disease (MBD) of prematurity remains a signiﬁcant problem for preterm, chronically ill
neonates. The deﬁnition and recommendations for screening and treatment of MBD vary in the litera-
ture. A recent American Academy of Pediatrics Consensus Statement may help close the gap in insti-
tutional variation, but evidence based practice guidelines remain obscure due to lack of normative data
and clinical trials for preterm infants. This review highlights mineral homeostasis physiology, current
recommendations in screening and monitoring, prevention and treatment strategies, and an added
perspective of a bone health team serving a high volume referral neonatal intensive care center.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Background/deﬁnition
Despite notable nutritional and medical improvements,
metabolic bone disease (MBD) of prematurity remains a signiﬁ-
cant comorbidity in preterm, low birth weight, and chronically ill
neonates. MBD has been estimated to occur in 16e40% of very
low birth weight (VLBW, <1500 g) and extremely low birth
weight (ELBW, <1000 g) infants [1,2]. The exact incidence re-
mains unknown, in part from a lack of consensus on the deﬁni-
tion of MBD (also known as osteopenia or rickets of prematurity).
We deﬁne MBD as decreased bone mineral content relative to the
expected level of mineralization for a fetus or infant of compa-
rable size or gestational age seen in conjunction with biochemical
and/or radiographic changes (Figure 1). Most commonly, MBD
occurs as a result of inadequate calcium and phosphorus stores
exacerbated by inadequate intake and the high degree of skeletal
growth occurring in the weeks following birth [3]. The etiology ofP, Tubular reabsorption of
hosphatase; VLBW, Very low
BY-NC-ND license (http://
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interest to disclose.
labria).
Published by Elsevier Inc. All righMBD is multifactorial with numerous associated risk factors,
including but not limited to the degree of prematurity, low birth
weight, exposure to medications that can alter mineral levels,
immobilization, long term parenteral nutrition, and delayed
establishment of full feeds. MBD typically presents within 6e16
weeks after birth [1]. As MBD advances, biochemical changes
intensify. These changes commonly include hypophosphatemia,
hyperphosphatasia, and secondary hyperparathyroidism, which
may be accompanied by rachitic changes and/or fractures. How-
ever, it may go unrecognized as a signiﬁcant loss of bone
mineralization is needed before characteristic changes are visible
on radiograph [4]. Inadequate bone mineralization during this
period may compromise pulmonary status and contribute to poor
growth.
Fetal skeletal development
The fetal skeleton develops early in gestation with the prolif-
eration and differentiation of cartilaginous precursors and pro-
gressive ossiﬁcation. These processes are tightly regulated by
hormones [e.g. growth hormone and parathyroid hormone (PTH)],
cytokines, and vitamins (A, D, C) [5]. An adequate nutritional and
vascular supply is also critical. Indeed, conditions associated with
chronic placental damage, such as preeclampsia, intrauterine
growth restriction, and chorioamnionitis, are associated with an
increased risk of MBD potentially via decreased in utero phosphate
transport [6].ts reserved.
Figure 1. Radiographs e A) Normal mineralization of the proximal humerus in a six month old former full term infant; growth plate formation is shown (arrow), B) Early
demineralization in the humerus of a six month old former ELBW preterm infant with periosteal reaction (arrow), C) and D) Severe demineralization with features of rickets
including cupping and fraying of metaphyses, healing fracture (arrow), and cortical thinning. Images are courtesy of Dr. Janet Reid, The Children’s Hospital of Philadelphia.
S.E. Rustico et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 85e9186Bonemineralization occurs predominantly in the third trimester
with calcium and phosphorus being the main minerals required.
Levels of both are higher in the fetus due to active transport from
mother to fetus. The main regulator of calcium transport appears to
be parathyroid hormone-related peptide, though PTH also plays a
role. The conversion of 1,25-dihydroxyvitamin D [1,25(OH)2D], the
active form of vitamin D, from its precursor 25-hydroxyvitamin D
[25(OH)D], also promotes calcium ﬂow across the placenta. The
mechanisms for phosphorus transfer are less clearly understood
though an active transport process mediated in part by PTH is
suspected [7]. The end result is that nearly 80% of calcium and
phosphorus transfer occurs between the 24th week of gestation
and term [8]. Not surprisingly, infants born prematurely often fail to
achieve adequate stores of these minerals.
Postnatal mineral homeostasis
Regardless of gestational age and despite continued mineral
demand, there is an immediate drop in calcium at birth, with a
nadir reached by 24e30 h in preterm infants [9]. PTH levels increase
in response to decreased plasma calcium levels. In the kidney, PTH
enhances calcium reabsorption while decreasing phosphate reab-
sorption, leading to urinary phosphate wasting. It also increases the
synthesis of 1,25(OH)2D, which leads to intestinal calcium andphosphate absorption. In bone, PTH stimulates resorption and
subsequent release of calcium and phosphate. Overall, as its actions
are greatest in the kidney, the net effects of increased PTH levels are
hypercalcemia and hypophosphatemia. With insufﬁcient calcium
intake over time, these biochemical changes can persist and
accompany MBD.
The most common biochemical changes of MBD include hypo-
phosphatemia and hyperphosphatasia and are frequently associ-
ated with insufﬁcient mineralization. Hypophosphatemia
manifests as the earliest marker of disrupted mineral metabolism,
as early as 7e14 days after birth [10]. Phosphate deﬁciency sup-
presses PTH, thereby preventing urinary phosphate wasting but
activates synthesis of 1,25(OH)2D to increase intestinal calcium and
phosphate reabsorption. Thus, phosphate deﬁciency disrupts cal-
cium balance, potentially leading to hypercalcemia, hypercalciuria,
and nephrocalcinosis. The kidney responds to phosphate deﬁcient
states by increasing phosphate reabsorption. Tubular reabsorption
of phosphate (TRP) is a measure of the fraction of ﬁltered phosphate
that is reabsorbed and is a calculated from the ratio of phosphorus
and creatinine in serum and urine (Table 1). As such, an elevated
TRP with hypercalcemia and hypercalciuria can suggest inadequate
phosphorus intake.
These changes are often accompanied by hyperphosphatasia.
Alkaline phosphatase (ALP) is the sum of bone, liver and intestinal
Table 1
Screening and monitoring of MBD
Level of interest Key points
ALP >800 IU/L or >600 and trending up High values associated with MBD
Can be elevated in liver disease and may consider bone speciﬁc alkaline
phosphatase if etiology unclear
Calcium (albumin corrected) <8.5 or > 10.5 [37] Often normal (compensation). High levels indicate over-treatment. Low
values suggest low intake or increased losses
Phosphorus <5.5 mg/dl (1.8 mmol/l) [14,38] Low levels correlate with MBD
TRP 1-(Uphos/Sphos  Scr/UCr) >95% [14] in setting of lower
phosphorus (phos < 5.5)
Should be obtained at the same time as the serum sample. High TRP
suggests low urinary phosphate wasting (low serum phos, or low PTH). Low
TRP suggests increased urinary phosphatase wasting (often from high PTH in
this population)
Urine Ca:Cr (spot) 3.8 mmol/mmol (95%tile) [14] (1.3 mg/mg) Screen for hypercalciuria due to excess calcium/calcitriol intake or side
effect of meds (ex. Loop diuretic, methylxanthine)
PTH >100 pg/ml No reference range for preterm infants
Adult ULN ranges from 50 to 88 pg/ml [8,16]
Elevated in subclinical hypocalcemia
25(OH) Vitamin D <30 ng/ml Values < 20 ng/ml indicate deﬁciency
Additional screening tests
1,25-(OH)2 vitamin D c-terminal procollagen peptide Osteocalcin
X-ray Bone speciﬁc alkaline phosphatase
DXA Tibial quantitative ultrasound
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resenting a marker of bone mineralization [5]. While ALP physio-
logically increases over the ﬁrst few weeks and plateaus around 5e
6 weeks, hyperphosphatasia beyond 6 weeks typically represents
inadequate mineral intake and often accompanies MBD. However,
ALP levels have not been shown to correlate to the degree of
hypomineralization. Rachitic changes are more commonly associ-
ated with greater ALP levels (>800 IU/l) but can also be seen at
lower levels (<600 IU/l) [11]. ALP levels may be deceivingly low in
the setting of zinc deﬁciency or glucocorticoid exposure and should
not be the only factor used in screening for MBD.
In a subset of high risk infants (e.g. chronic lung disease on long
term furosemide), calcium deﬁciency can accompanyMBD and lead
to metabolic changes associated with secondary hyperparathy-
roidism. In these neonates, elevations in PTH lead to urinary
phosphate wasting and an associated low TRP with hypo-
phosphatemia. Increased PTH levels will trigger increased plasma
calcium levels due to increased bone resorption and increases in
renal and intestinal calcium absorption. As such, isolated plasma
calcium levels may not be a helpful screening marker for infants at
risk for MBD as a normal plasma level does not ensure adequate
mineral intake.
Less commonly, renal tubular damage can cause urinary phos-
phate wasting and an associated low TRP and hypophosphatemia.
However, unlike those with calcium deﬁciency, PTH levels are
typically normal in this subset of patients.
Screening and monitoring
The American Academy of Pediatrics (AAP) recently released
guidelines for calcium and vitamin D requirements of enterally fed
preterm infants [12]. Many screening tests are available (Table 1)
and neonatologists recognize the importance of maximizing bone
health. Yet, there is a lack of consistency with regards to optimal
screening, treating, and prevention of MBD. Indeed, wide practice
variation in the United Kingdomwas reported by Harrison et al. [6]
Encouragingly, a survey by Kelly et al. of U.S. providers in Level 3
neonatal intensive care units (NICUs) done prior to the release of
the AAP guidelines revealed that practices were nearly in line with
the AAP recommendations. However, there was a no consensus
regarding both diagnosis and timing of treatment initiation [13].
Choosing whom to screen is driven by risk factors (Figure 2)
[12,14]. Deciding the best screening test can be a challenge. ALP hasbeen shown to be suggestive of rickets at very high levels>1000 IU/
l [11]; speciﬁcity improves when ALP is used in combination with
serum phosphorus levels. ALP >900 IU/l with serum phosphorus
levels <5.6 mg/dl (<1.8 mmol/l) yields 100% sensitivity with 70%
speciﬁcity [15]. Given lack of consensus on screening, Harrison et al.
has recommended weekly measurement of serum calcium, phos-
phorus, ALP, and TRP [6].
In addition, serum PTH levels may be a useful marker in iden-
tifying ELBW neonates at risk for MBD (Table 1) [16]. Not only can
PTH be a marker of secondary hyperparathyroidism, but in
conjunction with TRP can help distinguish the underlying cause of
hypophosphatemia. A low TRP with a high PTH would suggest an
underlying calcium deﬁciency. Meanwhile, a high TRP with low or
normal PTH would indicate phosphorus deﬁciency.
Monitoring of biochemical markers is not only necessary for
diagnosis and assessment of individual therapeutic response, but
also to screen for complications of mineral supplementation.
Complications can arise when mineral supplies are increased too
quickly or after prolonged periods of interrupted enteral nutrition,
leading to electrolyte imbalance and rapid augmentation of calcium
and phosphorus absorption [17]. There are no clear monitoring
guidelines, though it seems reasonable to monitor labs every 1e2
weeks. Abrams et al. recommend following serum phosphorus and
ALP weekly or biweekly [12]. Land et al. recommend calcium and
phosphorus measurements, accompanied by urinary calcium and
phosphorus excretion, weekly in premature infants under 3 weeks
and biweekly in those over 3 weeks [17]. Once mineral supple-
mentation or other treatment is started, monitoring and thera-
peutic goals are individualized to the underlying deﬁciency and
speciﬁc treatment. For infants with hypophosphatemia, phos-
phorus supplementation can be adjusted to reach a target serum
phosphorus of>5.5 mg/dl. For infants on calcium or calcitriol, goals
are to normalize PTH levels, monitor for hypercalciuria, and to
normalize phosphorus levels by limiting urinary phosphorus
wasting, as evidenced by increases in TRP.
Vitamin D typically can be assessed less frequently. While health
experts have focused on vitamin D in recent years, much remains
unknown regarding its physiology in preterm infants. As vitamin D
is readily transferred across the placenta, newborn 25(OH)D levels
are about 50e70% of maternal levels regardless of gestational age
[18]. In the majority of cases of MBD, 25(OH)D levels are normal,
and interestingly, serum 25(OH)D levels have been shown to be
similar in premature infants with and without rickets [19]. As such
Figure 2. Algorithm for screening and monitoring MBD.
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prior research has emphasized supplementation rather than
vitamin D status, with no uniform consensus deﬁning levels of
insufﬁciency and adequacy [18]. Ongoing efforts will hopefully
clarify some of these unknowns.
Indications for screening for vitamin D deﬁciency in preterm
infants include maternal vitamin D deﬁciency (if known), short gut
syndrome and other malabsorptive conditions that may impact
vitamin D absorption, and anticonvulsant therapies that may in-
crease vitamin D catabolism (e.g. phenobarbital). Further, screening
is beneﬁcial to identify the subset of infants who are at risk of
developing vitamin D intoxication. In particular, those receiving
preterm formulas and fortiﬁed breast milk where total vitamin D
intake may exceed 1000 units/day when receiving concurrent sup-
plementation are at greatest risk of intoxication. When measured,
25(OH)D rather than 1,25(OH)2D should be the marker measured
exclusively for vitamin D status as the latter is not closely associated
with overall outcomes of vitamin D exposure [12]. In addition,
1,25(OH)2D levels can be normal until profound depletion occurs.
Radiographs, typically done as part of standard clinical care, can
reveal various degrees of MBD, including demineralization or
“osteopenia,” rachitic changes, and/or fractures (Figure 1). While
some fractures can be acute with associated pain or diminished
movement, fractures are more commonly healing and without
associated symptoms [20]. The AAP Clinical Report recommends
rechecking radiographs every 5e6 weeks until improved mineral-
ization [12].
Prevention and treatment of MBD
The primary prevention and treatment strategy for MBD is
similar: optimizing nutrition, speciﬁcally calcium, phosphorus, and
vitamin D. Limiting prolonged exposure to commonly prescribedmedications that further reduce mineral stores (e.g. loop diuretics
and methylxanthines) or increase bone resorption (e.g. glucocor-
ticoids) is equally important [5].
The goal is not only to maintain normal serum levels but also
mimic in utero bone accretion rates for calcium and phosphorus.
Recommendations for calcium, phosphorus, and vitamin D vary
globally with higher calcium and phosphorus and lower vitamin D
goals for intake in the United States compared to Europe (Table 2).
Fortiﬁed breast milk and preterm formulas are generally preferred
as formulas not designed for premature infants (e.g. soy or
elemental formulas) lack the adequate calcium and phosphorus
content needed by a preterm infant [12].
Fortiﬁcation remains essential to provide adequate mineral
intake. Even 180e200 ml/d feedings of unfortiﬁed human milk
likely only provide 1/3 the level of in utero calcium and phosphorus
accretion [21]. This is despite 60% calcium and 80% phosphorus
absorption from human milk by the newborn. Care must also be
taken when using unfortiﬁed banked human donor milk due to its
lower phosphorus content than unbanked human milk [5]. Infants
on full feeds with preterm formula or fortiﬁed maternal breast milk
reach an optimal level of mineral intake with approximately 180e
220 mg/kg/day calcium and 100e130 mg/kg/day phosphorus [12].
Despite reaching this degree of intake, some children still develop
MBD, especially in the setting of critical illness, and may require
targetedmineral supplementationwith calcium and/or phosphorus
(Table 3).
More aggressive feeding strategies aimed at promoting growth
and avoiding a catabolic state, such as earlier introduction of pro-
tein supplementation in TPN and enteral feedings, have become
commonplace in NICUs. One effect of the increased protein intake is
an increased cellular uptake of phosphorus. Recent observational
studies by Ichikawa et al. and Bonsante et al. demonstrated lower
serum phosphorus levels in the ﬁrst week of life associated with a
Table 2
Recommended enteral calcium, phosphorus, and vitamin D intakes
Calcium (mg/kg/day) Phosphorus (mg/kg/day) Vitamin D (IU/day)
LSRO 2002 [39] 150e220 100e130 90e320 IU/kg/day
Atkinson and Tsang 2005 [40] 120e200 70e120 200e1000
Canadian Paediatric Society 1995 [41] 4e6 mmol/kg (160e240)a 2.5e3.8 mmol/kg (78e118)b 400e800
Rigo and Senterre 2006 [3] 100e160 60e90 800e1000
Abrams (AAP) 2013 [12] 150e220 75e140 200e400
a Calcium mmol to mg: multiply by 40.
b Phosphorus mmol to mg: multiply by 32.
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premature infants [22,23]. The impact of this decrease in circulating
phosphorus in contributing to MBD and whether it can be pre-
vented with phosphorus supplementation is unknown.
Biochemical markers can help determine the most appropriate
form of supplementation. Phosphorus supplementation should be
considered with hypophosphatemia in the setting of low or normal
PTH levels and high TRP, which suggests a lack of urinary phosphate
wasting due to inadequate intake. Treatment is indicated for values
consistently less than 4 mg/dl but can be considered if values fall
below 5.5 mg/dl, especially with associated hyperphosphatasia.
Correcting this imbalance is critical to promote bonemineralization
and prevent hypercalciuria [12]. Individual responses may vary
depending on clinical status, gut pH, and absorption and tolerance
of the individual supplement. Potassium phosphate, typically the
intravenous formulation administered enterally as solution, is the
preferred form of phosphorus supplementation due to gut intol-
erance of other available phosphate salts. Due to national shortages,
alternative formulations, such as tablet or powder forms, may be
used. Children, especially those on potassium-sparing diuretics,
must be monitored closely for electrolyte abnormalities due to
additional sodium and potassium in these alternative formulations.
Calcium supplementation can be considered in the setting of sec-
ondary hyperparathyroidism and low TRP. Again, serum calcium
levels typically remain normal or even high due to a compensatory
secondary hyperparathyroidism.
For those on parenteral nutrition, normal serum levels can be
achieved but mineral intake fails to reach even 50% of rates of in
utero mineral retention due to the poor solubility of available
mineral salts in the U.S. Prior studies have shown that parenteral
mineral retention is affected by greater mineral intake and cal-
cium:phosphorus ratio, with a preferred ratio of 1.7:1 providing
greater retention when compared to 1.3:1 or 2:1 [24].
Themost recent AAP recommendation for daily vitamin D intake
is 200e400 IU/day for preterm infants, but among various sources
the amount ranges from 90 IU/day to 1000 IU/day (Table 2). For
VLBW and ELBW infants, TPN in the U.S. will provide 160 IU/kg
which could lead to deﬁciency in those infants requiring prolonged
TPN without enteral feedings. Even with full enteral nutrition,
supplementation beyond human milk fortiﬁcation or higher caloric
density preterm formulasmay still be required to achieve a targeted
intake. This can be achieved through the use of a multivitamin or
individual vitamin D supplement.Table 3
Supplementation with calcium and phosphorus when further increase cannot be made i
Starting dose (mg/kg/day) Maxim
Elemental calcium
Enteral (E)
Parenteral (P)
20 70e10
Phosphorus 10e20 40e50
Clinical correlation is warranted (this may not be suitable for all). Monitoring of serum c
critical.For the subset of patients on TPN with secondary hyperpara-
thyroidism, calcitriol may provide adjunctive therapy [25]. Calci-
triol (starting dose 0.05mcg/kg/day, max dose 0.2mcg/kg/day) may
suppress PTH and minimize phosphorus wasting while increasing
intestinal calcium and phosphorus. Thismay be a particularly useful
adjunct in this subset of patients that cannot receive enteral
supplements.
Nonpharmologic therapies also play an integral part in the
treatment of MBD. The role of mechanical stimulation to promote
bone growth cannot be overlooked. Fetal movements against the
uterine wall help ensure appropriate bone mineral content and
muscular development [26]. These loading movements cannot be
replicated in the extrauterine environment of the NICU. Physical
therapy may provide necessary stimulation lost in the absence of
the uterine wall resistance that helps ensure appropriate bone
mineral content and muscular development. Programs reviewed by
Schulze done in “well” preterm infants with activity ranging from 5
to 15 min per day for 3e8 weeks duration showed an increase in
weight and length and improved short-term bone mineralization
[27]. Similarly, Tosun et al. found improved tibial strength
(measured by ultrasonography) and mid-upper arm circumference
in VLBW infants [28].
Post-discharge
Discharge timing is dependent on clinical status, with the ma-
jority of stable VLBW and ELBW infants discharged home between
36 and 40 weeks posteconception. Extrauterine growth failure
continues to be problematic in neonatal follow-up. Poor growth has
been correlated with poor development and chronic diseases in
adulthood [29e31], with the greatest risk in thosewith intrauterine
or postnatal growth retardation. Bone mineralization generally
improves rapidly in the ﬁrst few months of life, reaching values
appropriate for body size and similar to healthy term infants
[32,33]. Thus, post discharge nutrition will often be driven by
growth parameters. Many infants with BW >1500 g do well with
exclusive breastfeeding or routine infant formula after discharge
[12]. On the other hand, most VLBW and ELBW infants are dis-
charged home on transitional formula and/or continued fortiﬁca-
tion. This is often an individualized approach based on clinical
experience as there is limited research with which to guide pro-
viders. Enhanced formula continued until term beneﬁts growth and
bone health in otherwise well former preterm infants, but the datan diet alone
um dose (mg/kg/day) Dosage forms
0 [12,16] E: calcium glubionate, calcium carbonate
P: calcium gluconate
E/P: potassium phosphate
alcium (ionized and/or albumin corrected), serum phosphorus, urinary calcium are
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formula or breast milk fortiﬁcation may be empirically provided
until 40e52 weeks post-conceptional age [33] or up to 6 months if
ongoing concerns for growth exist [35]. There are indications for
transitioning to term formula or exclusive breastfeeding sooner.
Some consider cutting back once weight reaches 3 kg due to con-
cerns of Vitamin A exceeding the upper limit of recommended
intake [12,36].
While growth parameters drive decisions on nutritional sup-
port, the frequency of biochemical monitoring for MBD is based on
severity. ALP measured 2e4 weeks post discharge is appropriate in
exclusively breastfed former VLBW infants with consideration of
direct mineral supplementation if ALP >800e1000 IU/l [12]. Closer
follow-up is warranted in those with moderate to severe MBD or
with ongoing risk for poor bone mineralization (i.e. TPN depen-
dence, loop diuretics, glucocorticoids, etc.) as they may require
extended fortiﬁcation or direct mineral supplementation. Those
with ongoing use of direct calcium and/or phosphorus supple-
mentation or those on calcitriol at discharge should have
biochemical markers monitored as previously suggested (Figure 2).
Clinical context will determine frequency of monitoring. The sup-
plements should be weaned as biochemical markers normalize to
avoid therapeutic consequences including hypercalciuria and
nephrocalcinosis. In these more complex cases, we recommend a
multidisciplinary approach that includes a registered dietitian with
expertise in neonatal and/or bone health.
Conclusion
While the exact incidence remains unknown, MBD of prema-
turity remains a signiﬁcant problem for preterm, chronic ill neo-
nates. Treatment strategies include the optimization of nutrition,
supplementation with calcium, phosphorus and vitamin D, and
promotion of age appropriate physical therapy. Early identiﬁcation
and prevention of MBD remains important to prevent short-term
and potential long-term complications, but up until the 2013 AAP
recommendations, a lack of consensus existed on screening stra-
tegies. Given the signiﬁcant knowledge gaps regarding screening,
prevention, and long-term sequelae as infants survive at increas-
ingly earlier gestational ages and lower birth weights, we hope that
new AAP guidelines will provide consistency in clinical practice and
promote research that generates evidence upon which to reﬁne
these guidelines.
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